Interleukin 18: Friend or foe in cancer

被引:50
|
作者
Palma, Giuseppe [1 ,5 ]
Barbieri, Antonio [1 ]
Bimonte, Sabrina [1 ]
Palla, Marco [2 ]
Zappavigna, Silvia [4 ]
Caraglia, Michele [4 ]
Ascierto, Paolo A. [2 ]
Ciliberto, Gennaro [3 ]
Arra, Claudio [1 ]
机构
[1] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, Struttura Semplice Dipartimentale Sperimentaz Ani, Milan, Italy
[2] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, UOC Oncol Med & Terapie Innovat, Milan, Italy
[3] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, Milan, Italy
[4] Univ Naples 2, Dipartimento Biochim & Biofis & Patol Gen, I-80138 Naples, Italy
[5] CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy
来源
关键词
Tumor immunology; Immune regulation; GAMMA-INDUCING FACTOR; MURINE MELANOMA-CELLS; ENDOTHELIAL GROWTH-FACTOR; HUMAN GASTRIC-CANCER; IFN-GAMMA; SIGNALING PATHWAYS; INTERFERON-GAMMA; BINDING-PROTEIN; ANTITUMOR-ACTIVITY; IMMUNE ESCAPE;
D O I
10.1016/j.bbcan.2013.09.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the last few years, the field of tumor immunology has significantly expanded and its boundaries, never particularly clear, have become less distinct. Although the immune system plays an important role in controlling tumor growth, it has also become clear that tumor growth can be promoted by inflammatory immune responses. A good example that exemplifies the ambiguous role of the immune system in cancer progression is represented by interleukin 18 (IL-18) that was first identified as an interferon-gamma-inducing factor (IGIF) involved in T helper type-1 (Th1) immune response. The expression and secretion of IL-18 have been observed in various cell types from immune cells to circulating cancer cells. In this review we highlighted the multiple roles played by IL-18 in immune regulation, cancer progression and angiogenesis and the clinical potential that may result from such understanding. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:296 / 303
页数:8
相关论文
共 50 条
  • [41] Autophagy: Cancer's Friend or Foe?
    Bhutia, Sujit K.
    Mukhopadhyay, Subhadip
    Sinha, Niharika
    Das, Durgesh Nandini
    Panda, Prashanta Kumar
    Patra, Samir K.
    Maiti, Tapas K.
    Mandal, Mahitosh
    Dent, Paul
    Wang, Xiang-Yang
    Das, Swadesh K.
    Sarkar, Devanand
    Fisher, Paul B.
    ADVANCES IN CANCER RESEARCH, VOL 118, 2013, 118 : 61 - 95
  • [42] Neutrophil Engulfment in Cancer: Friend or Foe?
    Lu, Tong
    Li, Wei
    CANCERS, 2025, 17 (03)
  • [43] Neutral Sphingomyelinases in Cancer: Friend or Foe?
    Clarke, Christopher J.
    SPHINGOLIPIDS IN CANCER, 2018, 140 : 97 - 119
  • [44] Inflammasome: Cancer's friend or foe?
    Terlizzi, Michela
    Casolaro, Vincenzo
    Pinto, Aldo
    Sorrentino, Rosalinda
    PHARMACOLOGY & THERAPEUTICS, 2014, 143 (01) : 24 - 33
  • [45] Estrogen in Prostate Cancer - Friend or Foe?
    Corey, Eva
    CURRENT CANCER THERAPY REVIEWS, 2006, 2 (04) : 341 - 349
  • [46] Fibroblasts in cancer dormancy: foe or friend?
    Li Dai
    Mao Li
    Wei-long Zhang
    Ya-Jie Tang
    Ya-ling Tang
    Xin-hua Liang
    Cancer Cell International, 21
  • [47] Rho GTPases in cancer: friend or foe?
    Julius H. Svensmark
    Cord Brakebusch
    Oncogene, 2019, 38 : 7447 - 7456
  • [48] Role of interleukin-21 in HBV infection: friend or foe?
    Yongyin Li
    Libo Tang
    Jinlin Hou
    Cellular & Molecular Immunology, 2015, 12 : 303 - 308
  • [49] Interleukin-33: Friend or Foe in Gastrointestinal Tract Cancers?
    Pisani, Laura Francesca
    Teani, Isabella
    Vecchi, Maurizio
    Pastorelli, Luca
    CELLS, 2023, 12 (11)
  • [50] Interleukin-1 Beta-A Friend or Foe in Malignancies?
    Bent, Rebekka
    Moll, Lorna
    Grabbe, Stephan
    Bros, Matthias
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)